RENFLEXIS. Same dosing as\u00a0REMICADE\u00a0(infliximab)<\/h1>\n\n\n\n
Scroll to view the recommended dosing regimens below. Please see the Prescribing Information for full details on dosing and administration.<\/p>\n\n\n\n
RENFLEXIS is an FDA-approved biosimilar of REMICADE based on data demonstrating that it is highly similar and that there are no clinically meaningful differences in safety and effectiveness between the two infliximab products.<\/strong><\/p>\n\n\n\n\n\n\n\n
\n
\n<\/figure>\n<\/div>\n\n\n\n
\n
General information<\/strong><\/h4>\n\n\n\n
\n
Prior to initiating RENFLEXIS in pediatric and adult patients, update vaccinations in accordance with current vaccination guidelines<\/li>\n\n\n\n
Prior to treatment, ensure appropriate personnel and medication are available to treat reactions (eg, hypersensitivity, other reactions) that occur during infusion and shortly after infusion *<\/sup>,\u2020<\/sup><\/li>\n\n\n\n
RENFLEXIS is supplied as a sterile, preservative-free, white, lyophilized powder for intravenous infusion after reconstitution and dilution<\/li>\n\n\n\n
RENFLEXIS infusion should begin within 4 hours of reconstitution and dilution<\/li>\n\n\n\n
RENFLEXIS infusion must be administered intravenously for at least 2 hours with an infusion set with an in-line, sterile, non-pyrogenic, low-protein-binding filter (pore size of 1.2 \u03bcm or less)<\/li>\n\n\n\n
Given that the vials do not contain antibacterial preservatives, discard any unused portion of the infusion solution (do not store for reuse)<\/li>\n\n\n\n
No physical biochemical compatibility studies have been conducted to evaluate the coadministration of RENFLEXIS with other agents. RENFLEXIS should not be infused concomitantly in the same intravenous line with other agents<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n\n
*<\/sup>For mild to moderate reactions during the infusion, consider slowing or stopping the infusion. Upon resolution of these reactions, may reinitiate at a lower infusion rate and\/or with histamine-1 receptor antagonists, histamine-2 receptor antagonists, acetaminophen, and\/or corticosteroids. Discontinue the infusion if the mild to moderate reactions reoccur. \u2020<\/sup>Discontinue the infusion if severe hypersensitivity reactions occur during the infusion.<\/p>\n\n\n\n\n\n\n\n
In combination with methotrexate\u00a0<\/p>\n\n\n\n
RENFLEXIS 3 mg\/kg given as an intravenous induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 3 mg\/kg IV every 8 weeks thereafter for the treatment of adult patients with moderately to severely active rheumatoid arthritis<\/p>\n\n\n\n
\n
For patients who have an incomplete response, consideration may be given to adjusting the dosage up to 10 mg\/kg IV every 8 weeks or treating as often as every 4 weeks bearing in mind that risk of serious infections is increased at higher doses per infusion or more frequent dosing<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n\n\n\n\n\n
RENFLEXIS 5 mg\/kg given as an intravenous induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 5 mg\/kg IV every 6 weeks thereafter for the treatment of active ankylosing spondylitis in adult patients<\/p>\n<\/div>\n<\/div>\n\n\n\n
\n\n\n\n
\n
\n<\/figure>\n<\/div>\n\n\n\n
\n
Adult psoriatic arthritis<\/strong><\/h4>\n\n\n\n
With or without methotrexate\u00a0<\/p>\n\n\n\n
RENFLEXIS 5 mg\/kg given as an intravenous induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 5 mg\/kg IV every 8 weeks thereafter for the treatment of psoriatic arthritis in adult patients<\/p>\n<\/div>\n<\/div>\n\n\n\n
\n\n\n\n
\n
\n<\/figure>\n<\/div>\n\n\n\n
\n
Adult plaque psoriasis<\/strong><\/h4>\n\n\n\n
RENFLEXIS 5 mg\/kg given as an intravenous induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 5 mg\/kg IV every 8 weeks thereafter for the treatment of chronic severe (ie, extensive and\/or disabling) plaque psoriasis in adult patients<\/p>\n<\/div>\n<\/div>\n\n\n\n
\n\n\n\n
\n
\n<\/figure>\n<\/div>\n\n\n\n
\n
Adult ulcerative colitis<\/strong><\/h4>\n\n\n\n
RENFLEXIS 5 mg\/kg given as an intravenous induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 5 mg\/kg IV every 8 weeks thereafter for the treatment of adult patients with moderately to severely active ulcerative colitis<\/p>\n<\/div>\n<\/div>\n\n\n\n
RENFLEXIS 5 mg\/kg given as an intravenous induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 5 mg\/kg IV every 8 weeks for pediatric patients 6 years and older with moderately to severely active ulcerative colitis<\/p>\n<\/div>\n<\/div>\n\n\n\n
\n\n\n\n
\n
\n<\/figure>\n<\/div>\n\n\n\n
\n
Adult Crohn’s disease<\/strong><\/h4>\n\n\n\n
RENFLEXIS 5 mg\/kg given as an intravenous induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 5 mg\/kg IV every 8 weeks thereafter for the treatment of adults with moderately to severely active Crohn\u2019s disease or fistulizing Crohn\u2019s disease<\/p>\n\n\n\n
\n
For adult patients who respond and then lose their response, consideration may be given to treatment with 10 mg\/kg IV every 8 weeks<\/li>\n\n\n\n
Patients who do not respond by Week 14 are unlikely to respond with continued dosing and consideration should be given to discontinue RENFLEXIS in these patients<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n\n\n\n\n\n
\n
\n<\/figure>\n<\/div>\n\n\n\n
\n
Pediatric Crohn’s disease<\/strong><\/h4>\n\n\n\n
RENFLEXIS 5 mg\/kg given as an intravenous induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 5 mg\/kg IV every 8 weeks for pediatric patients 6 years and older with moderately to severely active Crohn\u2019s disease<\/p>\n<\/div>\n<\/div>\n\n\n\n
\n\n\n\n
FDA, US Food and Drug Administration; IV, intravenously.<\/p>\n\n\n\n
REMICADE is a trademark registered in the U.S. in the name of Janssen Biotech, Inc. Organon is not associated with this trademark owner.<\/p>\n","protected":false},"author":19,"featured_media":0,"parent":640,"menu_order":2,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"tags":[],"product_categories":[],"product_specialization":[],"customer_type":[],"class_list":["post-647","product","type-product","status-publish","hentry"],"acf":[],"yoast_head":"\n
Dosing and Administration for RENFLEXIS\u00ae (infliximab-abda)<\/title>\n<meta name=\"description\" content=\"Review the dosing and administration information for RENFLEXIS\u00ae (infliximab-abda), including time period toadminister RENFLEXIS.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/organonpro.com\/en-us\/product\/renflexis\/dosing-administration\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dosing\" \/>\n<meta property=\"og:description\" content=\"Review the dosing and administration information for RENFLEXIS\u00ae (infliximab-abda), including time period toadminister RENFLEXIS.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/organonpro.com\/en-us\/product\/renflexis\/dosing-administration\/\" \/>\n<meta property=\"og:site_name\" content=\"US\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-06T21:59:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/organonpro.com\/en-us\/wp-content\/uploads\/sites\/6\/2022\/04\/2037_IV_Icon_100px.webp?w=113\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dosing and Administration for RENFLEXIS\u00ae (infliximab-abda)","description":"Review the dosing and administration information for RENFLEXIS\u00ae (infliximab-abda), including time period toadminister RENFLEXIS.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/organonpro.com\/en-us\/product\/renflexis\/dosing-administration\/","og_locale":"en_US","og_type":"article","og_title":"Dosing","og_description":"Review the dosing and administration information for RENFLEXIS\u00ae (infliximab-abda), including time period toadminister RENFLEXIS.","og_url":"https:\/\/organonpro.com\/en-us\/product\/renflexis\/dosing-administration\/","og_site_name":"US","article_modified_time":"2024-11-06T21:59:14+00:00","og_image":[{"url":"https:\/\/organonpro.com\/en-us\/wp-content\/uploads\/sites\/6\/2022\/04\/2037_IV_Icon_100px.webp?w=113","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/organonpro.com\/en-us\/product\/renflexis\/dosing-administration\/","url":"https:\/\/organonpro.com\/en-us\/product\/renflexis\/dosing-administration\/","name":"Dosing and Administration for RENFLEXIS\u00ae (infliximab-abda)","isPartOf":{"@id":"https:\/\/organonpro.com\/en-us\/#website"},"primaryImageOfPage":{"@id":"https:\/\/organonpro.com\/en-us\/product\/renflexis\/dosing-administration\/#primaryimage"},"image":{"@id":"https:\/\/organonpro.com\/en-us\/product\/renflexis\/dosing-administration\/#primaryimage"},"thumbnailUrl":"https:\/\/organonpro.com\/en-us\/wp-content\/uploads\/sites\/6\/2022\/04\/2037_IV_Icon_100px.webp?w=113","datePublished":"2022-04-15T07:46:38+00:00","dateModified":"2024-11-06T21:59:14+00:00","description":"Review the dosing and administration information for RENFLEXIS\u00ae (infliximab-abda), including time period toadminister RENFLEXIS.","breadcrumb":{"@id":"https:\/\/organonpro.com\/en-us\/product\/renflexis\/dosing-administration\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/organonpro.com\/en-us\/product\/renflexis\/dosing-administration\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/organonpro.com\/en-us\/product\/renflexis\/dosing-administration\/#primaryimage","url":"https:\/\/organonpro.com\/en-us\/wp-content\/uploads\/sites\/6\/2022\/04\/2037_IV_Icon_100px.webp?w=113","contentUrl":"https:\/\/organonpro.com\/en-us\/wp-content\/uploads\/sites\/6\/2022\/04\/2037_IV_Icon_100px.webp?w=113"},{"@type":"BreadcrumbList","@id":"https:\/\/organonpro.com\/en-us\/product\/renflexis\/dosing-administration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/organonpro.com\/en-us\/"},{"@type":"ListItem","position":2,"name":"Products","item":"https:\/\/organonpro.com\/en-us\/product\/"},{"@type":"ListItem","position":3,"name":"RENFLEXIS\u00ae","item":"https:\/\/organonpro.com\/en-us\/product\/renflexis\/"},{"@type":"ListItem","position":4,"name":"Dosing"}]},{"@type":"WebSite","@id":"https:\/\/organonpro.com\/en-us\/#website","url":"https:\/\/organonpro.com\/en-us\/","name":"US","description":"Here for her health","publisher":{"@id":"https:\/\/organonpro.com\/en-us\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/organonpro.com\/en-us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/organonpro.com\/en-us\/#organization","name":"Organon Pro","url":"https:\/\/organonpro.com\/en-us\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/organonpro.com\/en-us\/#\/schema\/logo\/image\/","url":"https:\/\/organonpro.com\/en-us\/wp-content\/uploads\/sites\/6\/2022\/08\/ORGANON_PRO_1Color_Logo_White_RGB_M01.png","contentUrl":"https:\/\/organonpro.com\/en-us\/wp-content\/uploads\/sites\/6\/2022\/08\/ORGANON_PRO_1Color_Logo_White_RGB_M01.png","width":2579,"height":529,"caption":"Organon Pro"},"image":{"@id":"https:\/\/organonpro.com\/en-us\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.instagram.com\/hereforherhealth\/","https:\/\/www.linkedin.com\/company\/organon"]}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/organonpro.com\/en-us\/wp-json\/wp\/v2\/product\/647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/organonpro.com\/en-us\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/organonpro.com\/en-us\/wp-json\/wp\/v2\/types\/product"}],"author":[{"embeddable":true,"href":"https:\/\/organonpro.com\/en-us\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/organonpro.com\/en-us\/wp-json\/wp\/v2\/comments?post=647"}],"version-history":[{"count":27,"href":"https:\/\/organonpro.com\/en-us\/wp-json\/wp\/v2\/product\/647\/revisions"}],"predecessor-version":[{"id":6651,"href":"https:\/\/organonpro.com\/en-us\/wp-json\/wp\/v2\/product\/647\/revisions\/6651"}],"up":[{"embeddable":true,"href":"https:\/\/organonpro.com\/en-us\/wp-json\/wp\/v2\/product\/640"}],"wp:attachment":[{"href":"https:\/\/organonpro.com\/en-us\/wp-json\/wp\/v2\/media?parent=647"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/organonpro.com\/en-us\/wp-json\/wp\/v2\/tags?post=647"},{"taxonomy":"product_categories","embeddable":true,"href":"https:\/\/organonpro.com\/en-us\/wp-json\/wp\/v2\/product_categories?post=647"},{"taxonomy":"product_specialization","embeddable":true,"href":"https:\/\/organonpro.com\/en-us\/wp-json\/wp\/v2\/product_specialization?post=647"},{"taxonomy":"customer_type","embeddable":true,"href":"https:\/\/organonpro.com\/en-us\/wp-json\/wp\/v2\/customer_type?post=647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/organonpro.com\/en-us\/wp-content\/uploads\/sites\/6\/2022\/04\/2037_IV_Icon_100px.webp?w=113\"){kind=icon}
<\/figure>\n<\/div>\n\n\n\n![\"\"](\"https:\/\/organonpro.com\/en-us\/wp-content\/uploads\/sites\/6\/2022\/07\/Dosing_vial_postPRT-1.webp\")
<\/figure>\n<\/div>\n\n\n\n\n![\"\"](\"https:\/\/organonpro.com\/en-us\/wp-content\/uploads\/sites\/6\/2022\/07\/Dosing_vial_postPRT-1.webp?w=89\")
<\/figure>\n<\/div>\n\n\n\n\n![\"\"](\"https:\/\/organonpro.com\/en-us\/wp-content\/uploads\/sites\/6\/2022\/07\/Dosing_vial_postPRT-1-1.webp\")
<\/figure>\n<\/div>\n\n\n\n\n![\"\"](\"https:\/\/organonpro.com\/en-us\/wp-content\/uploads\/sites\/6\/2022\/07\/Dosing_vial_postPRT-1-2.webp\")
<\/figure>\n<\/div>\n\n\n\n\n